Sientra Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sientra Inc (SIEN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sientra Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 89M vs 2,673M combined for its competitors (3.2% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-14.7% annualized vs trailing 12 months), vs decelerating (-31.6%) for its tracked peer group.
- Growth: Sientra Inc generated -15.7% revenue growth year over year in Q3 2023, vs 12.9% for its competitors combined.
- Profitability: Its -77.6% net margin compares with -54.6% for the peer group.
- Peer revenue share: Sientra Inc accounted for 4.0% of combined revenue among its tracked peer group, down from 5.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.37M compares with $0.50M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SIEN Sales vs. its Competitors, Q3 2023
Sientra Inc reported revenue contraction of 15.69 % year on year in Q3 2023, below its competitors' combined revenue growth of 12.94 %.
With a net margin of -77.63 %, Sientra Inc reported lower profitability than its competitors (-54.61 %).
Sientra Inc generated 4.00 % of the combined sales of its peer group, down from 5.28 % a year earlier.
API endpoints for this dataset
Sientra Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Sientra Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sientra Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sientra Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sientra Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs -15.7% for Sientra Inc. Sientra Inc's share of combined industry revenue moved from 0.02% to 0.02%, a loss of 0.01 percentage points.
Sientra Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sientra Inc | No | Yes | No | Yes |
| Competitors combined (35) | ||||
| High-Confidence Competitors (3) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 7) | 62.50 % (5 of 8) | 37.50 % (3 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SIEN Stock Performance relative to its Competitors
SIEN Stock Performance relative to High-Confidence Competitors
SIEN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Avita Medical Inc | 282.9% | Outperformed |
| 2 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Pulse Biosciences Inc | 282.9% | Outperformed |
| 4 | Pro dex Inc | 282.9% | Outperformed |
| 5 | Opus Genetics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sientra Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Sientra Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Sientra Inc |
1.96 | 89.27 |
 Pulse Biosciences Inc |
3,615.70 | 1.19 |
 Biodexa Pharmaceuticals Plc |
3,264.23 | 0.38 |
 Establishment Labs Holdings Inc |
2,066.95 | 245.11 |
 Eton Pharmaceuticals Inc |
2,014.76 | 105.28 |
 Inmode Ltd |
863.21 | 370.50 |
| SUBTOTAL | 15,737.96 | 2,799.59 |
Sign in to see all competitors of Sientra Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sientra Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sientra Inc's Competitors Named by the Company
Competitive relationships identified from Sientra Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Establishment Labs Holdings Inc | Company report | 85% |
| SSP | Company report | 85% |
| Enaltus | Company report | 85% |
| Cutera Inc | Company report | 85% |
| Inmode Ltd | Company report | 85% |
| Apyx Medical Corp | Company report | 85% |
| Pro dex Inc | Company report | 85% |
| Mimedx Group Inc | Company report | 85% |
| Vycor Medical Inc | Company report | 85% |
| Envveno Medical Corporation | Company report | 85% |
| Venus Concept Inc | Company report | 85% |
| Airsculpt Technologies Inc | Company report | 85% |
| Strata Skin Sciences Inc | Company report | 85% |
| Nexgel Inc | Company report | 85% |
| Anika Therapeutics Inc | Company report | 85% |
| Aesthetic Medical International Holdings Group Limited | Company report | 85% |
Company report basis, confidence, active dates and source counts for Sientra Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Sientra Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Pulse Biosciences Inc | Single Reportable Segment 100.00 % |
| Ardelyx inc | Reportable 100.00 % |
| Anika Therapeutics Inc | Single Reportable Segment 100.00 % |
| Apyx Medical Corp | Surgical Aesthetics 92.44 % |
| Airsculpt Technologies Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sientra Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sientra Inc | 2 | 368,880 | -244,310 |
| Pulse Biosciences Inc | 3,616 | 10,216 | -690,138 |
| Biodexa Pharmaceuticals Plc | 3,264 | 34,636 | -765,608 |
| Establishment Labs Holdings Inc | 2,067 | 244,128 | -38,736 |
| Eton Pharmaceuticals Inc | 2,015 | 2,392,705 | 288,364 |
| Inmode Ltd | 863 | 7,561,122 | 1,914,918 |
| PEERS TOTAL | 15,736 | 504,528 | -175,886 |
Sientra Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Establishment Labs Holdings Inc | Non-US 63.84 % |
| Inmode Ltd | US 53.62 % |
| Avita Medical Inc | US 96.46 % |
| Anika Therapeutics Inc | US 59.77 % |
| Apyx Medical Corp | US 69.16 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sientra Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 42.59 % | 46.85 % (avg) | -4.3 pp |
| Operating Margin | -57.73 % | industry median | -42.4 pp |
| EBITDA Margin | -46.70 % | -6.45 % (avg) | -40.2 pp |
| Capital Intensity (Capex / Revenue) | 3.13 % | 7.11 % (avg) | -4.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sientra Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.0x | - |
| EV / EBITDA | - | 17.4x | - |
| P/B | -2.3x | 4.7x | -7.0x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -153.91 % | -6.49 % (avg) | -147.42 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Sientra Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenue Growth | 90.51 % | 86.43 % | 22.86 % | -14.88 % | 13.25 % | 12.23 % |
| Operating Margin | -172.10 % | -117.10 % | -123.74 % | -88.15 % | -59.87 % | -76.26 % |
| Return on Invested Capital | -48.06 % | -46.62 % | -47.19 % | -41.70 % | -36.05 % | -67.87 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sientra Inc's Strategic Group Map
Sientra Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Sientra Inc's trailing-12-month revenue growth of 7.3% and operating margin of -57.7% compares with an average of 1.3% growth and -59.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Sientra Inc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Sientra Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.13 % vs industry average 7.11 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Sientra Inc's dedicated Suppliers and Customers pages, not here.
Sientra Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Sientra Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sientra Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 42.4 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-14.7% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (51.40 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-31.6% annualized).
Methodology: see Methodology: SWOT Analysis.
Sientra Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sientra Inc | 0.19 | 0.91 | - |
| Pulse Biosciences Inc | 9.01 | 9.31 | - |
| Biodexa Pharmaceuticals Plc | 1.39 | 2.03 | - |
| Establishment Labs Holdings Inc | 0.95 | 3.26 | 13.16 |
| Eton Pharmaceuticals Inc | 0.64 | 1.48 | 0.95 |
| Inmode Ltd | 4.28 | 9.88 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sientra Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sientra Inc | Q3 2023 | -15.7 % | - |
| Pulse Biosciences Inc | Q2 2026 | - | - |
| Biodexa Pharmaceuticals Plc | Q4 2025 | - | - |
| Establishment Labs Holdings Inc | Q2 2026 | +31.7 % | - |
| Eton Pharmaceuticals Inc | Q2 2026 | +98.6 % | - |
| Inmode Ltd | Q4 2025 | -6.2 % | -48.2 % |
| PEERS TOTAL | -4.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sientra Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sientra Inc | Q3 2023 | -8.1 % | -74.1 % |
| Pulse Biosciences Inc | Q2 2026 | - | -26.8 % |
| Biodexa Pharmaceuticals Plc | Q4 2025 | - | -77.1 % |
| Establishment Labs Holdings Inc | Q2 2026 | +23.9 % | +76.2 % |
| Eton Pharmaceuticals Inc | Q2 2026 | +73.9 % | - |
| Inmode Ltd | Q4 2025 | +2.3 % | +45.3 % |
Sientra Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sientra Inc | - | - | - |
| Pulse Biosciences Inc | - | - | - |
| Biodexa Pharmaceuticals Plc | - | - | - |
| Establishment Labs Holdings Inc | - | - | - |
| Eton Pharmaceuticals Inc | 12.37% | 21.31% | 40.13% |
| Inmode Ltd | 12.24% | 13.49% | 13.73% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sientra Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sientra Inc | - | 0.02 |
| Pulse Biosciences Inc | - | 3,051.22 |
| Biodexa Pharmaceuticals Plc | - | 8,567.54 |
| Establishment Labs Holdings Inc | - | 8.43 |
| Eton Pharmaceuticals Inc | 157.56 | 19.14 |
| Inmode Ltd | 9.22 | 2.33 |
| PEERS AVERAGE | - | 5.62 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.